Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycaemic control and body weight in Japanese patients with type 2 diabetes

被引：0
|
作者：
Benson, C. T. [1 ]
Ohwaki, K. [2 ]
Furihata, K. [3 ]
Mimura, H. [2 ]
Oura, T. [2 ]
Imaoka, T. [2 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Eli Lilly Japan KK, Kobe, Hyogo, Japan
[3] P One Clin, Tokyo, Japan
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
734
引用
收藏
页码：S353 / S353
页数：1
相关论文
共 50 条
  • [1] Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycemic control and body weight in Japanese patients with T2DM
    Ohwaki, Kenji
    Furihata, Kenichi
    Mimura, Hanaka
    Oura, Tomonori
    Imaoka, Takeshi
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [2] Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM
    Ohwaki, Kenji
    Furihata, Kenichi
    Mimura, Hanaka
    Oura, Tomonori
    Imaoka, Takeshi
    [J]. DIABETES, 2019, 68
  • [3] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Michael A. Nauck
    David A. D‘Alessio
    [J]. Cardiovascular Diabetology, 21
  • [4] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Nauck, Michael A.
    D'Alessio, David A.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [5] Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
    Wong, Elaine
    [J]. JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2023, 19 (01):
  • [6] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes
    Ruotolo, G.
    Roth, K. D.
    Milligan, P. L.
    Lin, Y.
    Wilson, J. M.
    Pirro, V
    Duffin, K. L.
    Haupt, A.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 3056 - 3056
  • [7] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on metabolic profile in patients with type 2 diabetes
    Pirro, V.
    Willency, J. A.
    Wilson, J. M.
    Roth, K. D.
    Lin, Y.
    Collins, K. A. L.
    Ruotolo, G.
    Haupt, A.
    Newgard, C. B.
    Duffin, K. L.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S73 - S73
  • [8] The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes
    Wilson, Jonathan M.
    Lin, Yanzhu
    Considine, Gary
    Cox, Amy L.
    Bowsman, Lenden M.
    Robins, Deborah A.
    Riesmeyer, Jeffrey S.
    Haupt, Axel
    Duffin, Kevin
    Ruotolo, Giacomo
    [J]. CIRCULATION, 2020, 142
  • [9] Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
    Hartman, Mark L.
    Sanyal, Arun J.
    Loomba, Rohit
    Wilson, Jonathan M.
    Nikooienejad, Amir
    Bray, Ross
    Karanikas, Chrisanthi A.
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    [J]. DIABETES CARE, 2020, 43 (06) : 1352 - 1355
  • [10] Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
    Willard, Francis S.
    Douros, Jonathan D.
    Gabe, Maria
    Showalter, Aaron D.
    Wainscott, David B.
    Suter, Todd M.
    Capozzi, Megan E.
    van der Velden, Wijnand J. C.
    Stutsman, Cynthia
    Cardona, Guemalli R.
    Urva, Shweta
    Emmerson, Paul J.
    Holst, Jens J.
    D'Alessio, David A.
    Coghlan, Matthew P.
    Rosenkilde, Mette M.
    Campbell, Jonathan E.
    Sloop, Kyle W.
    [J]. JCI INSIGHT, 2020, 5 (17)
12345